Centene fondaparinux (Arixtra) Coverage Update

Coverage Criteria for Fondaparinux (Arixtra)

Initial Therapy - Thrombosis/Thromboembolism

Covered when ALL of the following are met for Initial Approval - Thrombosis/Thromboembolism:

Initial Approval Criteria - Thrombosis/Thromboembolism

Indication list (choose any): a) Thrombosis or thromboembolism prevention associated with: i. Cancer; ii. Unstable angina or myocardial infarction; iii. Major surgery (orthopedic or non-orthopedic); iv. Critical illness/ICU; v. Restricted mobility with acute illness; vi. Implanted vascular devices (e.g., central venous access, umbilical venous catheter, hemodialysis devices); OR b) Thrombosis or thromboembolism treatment; OR c) Short-term prophylaxis for transition to or from oral anticoagulation.
Enoxaparin trial exceptions (any): Enoxaparin trial not required if: a) enoxaparin is contraindicated; b) history of clinically significant adverse effects or allergy to LMWH or heparin (e.g., HIT); c) requested use is FDA labeled for fondaparinux but not enoxaparin (e.g., hip fracture surgery prophylaxis; PE treatment).
For Illinois HIM requests, the step therapy requirement does not apply as of 1/1/2026 per IL HB 5395.
Brand preference: If request is for Arixtra, member must use generic fondaparinux unless contraindicated or clinically significant adverse effects are experienced.

Approval duration: Medicaid/HIM - 6 months; Commercial - 6 months or duration of request, whichever is less.

Initial Therapy - Anticoagulation in Pregnancy

Covered when ALL of the following are met for Anticoagulation in Pregnancy (off-label):

Ante- and Postpartum anticoagulation: 1) One of listed pregnancy-related indications: acute venous thrombosis during current pregnancy; prior venous thrombosis; receiving long-term therapy with a vitamin K antagonist; prosthetic heart valve; inherited thrombophilia; antiphospholipid antibody syndrome; severe ovarian hyperstimulation syndrome post assisted reproduction; cesarean section (postpartum); or any indication in section I.A; 2) Member is pregnant or <6 months postpartum; 3) History of clinically significant adverse effects or allergy to LMWH or heparin (e.g., HIT); 4) If request is for Arixtra, member must use generic fondaparinux unless contraindicated or clinically significant adverse effects are experienced.

Approval duration: Antepartum to estimated delivery date; postpartum up to 6 months.

Continuation Therapy

Covered when ALL of the following are met for Continued Therapy - Thrombosis/Thromboembolism:

Continued therapy criteria: 1) Member currently receiving medication via Centene benefit or previously met initial approval criteria, or member is enrolled in continuity of care regulations; 2) Member is responding positively to therapy; 3) Continued use is limited to: a) VTE prophylaxis or treatment in presence of cancer; b) Past history of failed anticoagulation on warfarin; c) Any other indication in section I.A where bridging to warfarin is inappropriate or member has contraindication to warfarin and extended anticoagulation is required; 4) If request is for Arixtra, member must use generic fondaparinux unless contraindicated or clinically significant adverse effects are experienced.

Approval durations: Medicaid/HIM 6 months; Commercial 6 months or duration of request, whichever is less.

Covered Indications (adult and pediatric VTE; HIT)

Covered when clinical indications and dosing align with guideline-supported uses

On-label and guideline-supported indications: Fondaparinux is recommended for anticoagulation for management of acute superficial vein thrombosis; acute or chronic splanchnic vein thrombosis; acute DVT; acute catheter-related DVT; acute PE in cancer patients without contraindication; as monotherapy or for at least 5 days when given with warfarin until transition to warfarin; VTE prophylaxis for adult cancer patients admitted for medical or surgical hospitalizations; initial treatment for suspected or confirmed HIT following discontinuation of heparin-based products in clinically stable patients without contraindications and without hemodynamically unstable PE, limb-threatening thrombosis, or planned invasive procedures; transition to alternative therapy for HIT-stabilized patients.

Includes pediatric VTE treatment indication added in RT4.

Dosing Criteria

Dosing criteria

Adult prophylaxis dosing: DVT prophylaxis following hip fracture, hip replacement, knee replacement, and abdominal surgery: 2.5 mg subcutaneous once daily (maximum 2.5 mg/day).max 2.5 mg/day

Adult treatment dosing by weight: Acute DVT/PE treatment dosing (SC) based on body weight: <50 kg: 5 mg/day; 50 to 100 kg: 7.5 mg/day; >100 kg: 10 mg/day (maximum 10 mg/day).max 10 mg/day

Pediatric VTE dosing: VTE treatment dosing (SC) based on body weight for pediatric patients: 10 kg to 20 kg: 0.1 mg/kg per day.0.1 mg/kg/day

Policy RT4 added pediatric VTE indication.

Requests for non‑FDA approved indications that are not specifically addressed in this policy are not authorized unless the provider supplies adequate off‑label evidence of efficacy and safety. Supporting documentation must follow the referenced off‑label use policies (CP.CPA.09 for Commercial, HIM.PA.154 for Health Insurance Marketplace, CP.PMN.53 for Medicaid) or applicable evidence of coverage documents.

Fondaparinux is not recommended as initial treatment in patients with hemodynamically unstable pulmonary embolism (PE), limb‑threatening thrombosis, or when invasive procedures are planned during the initial HIT treatment period. Initial HIT treatment with fondaparinux is limited to clinically stable patients without these conditions.

Fondaparinux use is contraindicated in specified patient populations and is considered not medically necessary when any contraindication applies. Key contraindications include severe renal impairment (CrCl <30 mL/min) for prophylaxis or treatment of VTE, active major bleeding, bacterial endocarditis, thrombocytopenia with a positive anti‑platelet antibody test in the presence of fondaparinux, body weight <50 kg when used for VTE prophylaxis, and a history of serious hypersensitivity to Arixtra. The drug also carries a boxed warning for spinal/epidural hematomas.

Inclusion of procedure or billing codes in this policy is for informational purposes only and does not guarantee coverage. Payment decisions require that documentation and coding submitted with claims adequately support the medical necessity of the service and follow current professional coding guidance.

Coding and Billing

HCPCS Codes referencedHCPCS

J1652

Injection, fondaparinux sodium, 0.5 mg

Creatinine clearance — <30 mL/min

Creatinine clearance thresholdContraindication: creatinine clearance (CrCl) < 30 mL/min

Clinical implicationUse in prophylaxis or treatment of VTE is not recommended for patients with CrCl <30 mL/min

Source sectionAppendix C: Contraindications/Boxed Warnings

Body weight (prophylaxis only) — <50 kg

Body weight threshold (prophylaxis only)Contraindication: body weight < 50 kg for VTE prophylaxis

Clinical implicationFondaparinux prophylaxis dosing (2.5 mg) not appropriate for patients <50 kg

Provider Requirements and Actions

Prior Authorization

Prior Authorization Required

Prior authorization is required for fondaparinux (Arixtra) — requests must meet the policy criteria to be considered medically necessary. Provider must obtain prior authorization before dispensing or administration.

Prior authorization required for all indications covered by this policy.
Approval will be granted only when the member meets the criteria in the policy.

Prior Authorization

Prior Authorization and Approval Duration

Approval duration varies by product line: Medicaid/HIM — 6 months; Commercial — 6 months or duration of request, whichever is less. Duration adjustments for pregnancy and other conditions are noted in the policy updates.

Medicaid/HIM: 6 months
Commercial: 6 months or duration of request, whichever is less
For anticoagulation in pregnancy (Commercial) duration revised to antepartum until estimated delivery date or postpartum up to 6 months (per policy updates).

Initial Therapy Criteria

Initial Therapy

Initial approval criteria per section I (Thrombosis/Thromboembolism and Anticoagulation in Pregnancy).

Initial Therapy - Combined summary: Member must meet an eligible indication (section I.A or I.B), meet enoxaparin trial requirements or an allowed exception, and comply with brand-to-generic preference if Arixtra is requested. Pregnancy-specific approval durations apply when relevant.

Includes off-label adult and pediatric uses where specified.

Initial therapy

Initial treatment uses and dosing

Initial HIT treatment: Initial treatment for suspected or confirmed HIT following discontinuation of heparin-based products in clinically stable patients with no contraindications and without hemodynamically unstable PE, limb-threatening thrombosis, or planned invasive procedures.

Continuation and Transition Criteria

Continuation Therapy

Continued therapy criteria as specified in policy II.A and II.B for thrombosis and pregnancy respectively.

Continuation Therapy - Thrombosis: Member continues to meet Centene continuity criteria or prior initial approval, is responding positively, and continued use is limited to indications listed (including cancer-associated VTE, prior failed warfarin, or other I.A indications requiring extended anticoagulation). If request is for Arixtra, generic must be used unless contraindicated or adverse effects occur.

Approval durations: Medicaid/HIM 6 months; Commercial 6 months or duration of request, whichever is less.

Continuation Therapy - Pregnancy: For members who started fondaparinux for anticoagulation in pregnancy under initial criteria, continued use must comply with pregnancy-specific eligibility (member pregnant or <6 months postpartum) and brand-to-generic preference; approval duration antepartum to estimated delivery or postpartum up to 6 months.

Continuation/Transition

Transition/continuation guidance

Step Therapy and Exceptions

Step	Requirement / Exceptions
1	Failure of a trial of enoxaparin is required prior to approval of fondaparinux unless one of the following exceptions applies: (a) enoxaparin is contraindicated; (b) history of clinically significant adverse effects or allergy to LMWH or heparin (e.g., heparin‑induced thrombocytopenia); (c) the requested use is FDA‑labeled for fondaparinux but not enoxaparin (e.g., hip fracture surgery prophylaxis; PE treatment).

Step

Requirement / Exceptions

Failure of a trial of enoxaparin is required prior to approval of fondaparinux unless one of the following exceptions applies: (a) enoxaparin is contraindicated; (b) history of clinically significant adverse effects or allergy to LMWH or heparin (e.g., heparin‑induced thrombocytopenia); (c) the requested use is FDA‑labeled for fondaparinux but not enoxaparin (e.g., hip fracture surgery prophylaxis; PE treatment).

Jurisdiction	Step Therapy Bypass / Notes
[{"text":"Illinois (HIM)","status":""},{"text":"Per IL HB 5395, the step therapy requirement (trial of enoxaparin) does not apply for Health Insurance Marketplace (HIM) requests effective 1/1/2026; step therapy bypass added for Illinois HIM.
status":""}]

Background

Fondaparinux is a synthetic selective factor Xa inhibitor indicated for prevention of deep vein thrombosis (DVT) in patients undergoing hip fracture surgery, hip or knee replacement, and abdominal surgery at risk for thromboembolic complications, and for treatment of acute DVT and pulmonary embolism (PE) when used in conjunction with warfarin (with initial in‑hospital therapy for PE). The policy also reflects the recently added pediatric VTE treatment indication (patients ≥1 year and ≥10 kg) and includes guidance for off‑label anticoagulation in pregnancy under defined criteria.

Definitions and Abbreviations

LMWH — low molecular weight heparin

AbbreviationLMWH = low molecular weight heparin

ContextLMWH referenced as therapeutic alternative (e.g., enoxaparin) in appendices and step therapy rules

Source sectionAppendix A: Abbreviation/Acronym Key

DVT — deep vein thrombosis

AbbreviationDVT = deep vein thrombosis

Clinical contextDVT is a covered indication for fondaparinux (treatment and prophylaxis in specified settings)

Source section

Quantity Limits

fondaparinux — per dosing regimen (weight-based or fixed prophylaxis dosing)

Quantity basisDosing and quantity limits follow weight-based treatment dosing or fixed prophylaxis dosing per regimen

Adult dosing options (syringe strengths)Prefilled syringes available in 2.5 mg, 5 mg, 7.5 mg, and 10 mg strengths

Policy quantity statementQuantity limits specified per dosing regimen (weight-based treatment or fixed prophylaxis)

Site of Care and Formulation

Note

Prefilled syringes available — site of care options

Prefilled single‑dose syringes are available for subcutaneous administration (2.5 mg, 5 mg, 7.5 mg, 10 mg); administration site may be office, infusion center, hospital outpatient, or home depending on clinical context.

Product availability: single‑dose prefilled syringes in strengths 2.5 mg, 5 mg, 7.5 mg, 10 mg.
Site of care can include office, infusion center, hospital outpatient, or home per clinical context.

Revision History and Policy Updates

11.04.25annual_reviewLatest

Added pediatric VTE indication to coverage criteria (RT4) and updated step therapy bypass for Illinois HIM per IL HB 5395; revised Commercial approval duration for anticoagulation in pregnancy to antepartum to estimated delivery date or postpartum up to 6 months.

03.29.23policy_revision

Revised Commercial approval duration language for continued therapy to '6 months or duration of request, whichever is less.'

01.16.25annual_review

OpenPayer

Fondaparinux (Arixtra) prior authorization and coverage policy